Journals / Türk Geriatri Dergisi / 2015 / Cilt: 18 - Sayı: 1

UZUN DÖNEM BİFOSFONAT KULLANAN HASTALARDA UYLUK AĞRISI ATİPİK KIRIK HABERCİSİ OLABİLİR

THIGH PAIN MIGHT BE A PRODROMAL SYMPTOM OF ATYPICAL FRACTURE IN LONG TERM BISPHOSPHONATE USERS

Pages
87–91
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thigh pain in patients with prolonged bisphosphonate usage should alarm thephysicians for possible atypical fracture in the future

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Osteoporosis causes bones to lose their resilience, increases fragility andresults in bone fracture even with minimal trauma during daily activities.
📊
Key Findings & Data:We aimed to examinethe patients who were treated for atypical fractures in terms of long-term bisphosphonate usagefor the treatment of osteoporosis.Materials and Method: A retrospective study was conducted on 21 patients who underwent surgery for an atypical femur fracture between years 2007-2013.
💡
Conclusion & Impact:Thigh pain in patients with prolonged bisphosphonate usage should alarm thephysicians for possible atypical fracture in the future
🔬Design:Research Article
📍Scope:2007-2013 Verileri
⚙️Variables:Domain Parameters

Abstract

Introduction: Osteoporosis causes bones to lose their resilience, increases fragility andresults in bone fracture even with minimal trauma during daily activities. We aimed to examinethe patients who were treated for atypical fractures in terms of long-term bisphosphonate usagefor the treatment of osteoporosis.Materials and Method: A retrospective study was conducted on 21 patients who underwent surgery for an atypical femur fracture between years 2007-2013. Demographic data, history of bisphosphonate treatment, trauma type, patient complaints prior to fracture, fracture typeand the type of treatment used for the fracture were assessed. Results: The number of cases with atypical fractures was 21 and all of them had history ofprolonged bisphosphonate use. The number of female patients was 19, and 2 patients weremale, with an average age of 76.4 years. The number of patients with diaphyseal femur fractureswas 17 and 4 patients had subtrochanteric femur fractures. Among the patients that have beenusing a bisphosphonate, alendronate (70 mg) was the most frequently used medication. Theaverage length of bisphosphonate usage was 8.1 years and the average length of time thatelapsed until a fracture occurred subsequent to the start of drug usage was 7.2 years. Prior tofracture, all of the patients had complaints of thigh pain that lasted on average for 8.5 months. Conclusion: Bisphosphonates are one of the widely used agents used in the treatment ofosteoporosis. Thigh pain in patients with prolonged bisphosphonate usage should alarm thephysicians for possible atypical fracture in the future

Özet

Giriş: Osteoporoz kemiklerin elastikiyetini azaltarak ve frajilitesini artırarak günlük aktivitelersırasındaki minimal travmalarla bile kırık oluşmasına neden olur. Bu çalışmada atipik kırık nedeniyle tedavi edilen hastalarda uzun dönem bifosfonat kullanım öyküsü araştırıldı.Gereç ve Yöntem: Atipik femur kırığı nedeniyle 2007-2013 yılları arasında opere olan 21hasta demografik veriler, bifosfonat kullanım öyküsü, travma tipi, kırık öncesi semptomlar, kırıktipi ve kırık için uygulanan tedavi açısından incelendi. Bulgular: Atipik kırıklı 21 hastanın tümünde uzun süreli bifosfonat kullanım öyküsü mevcuttu. İncelenen vakaların 19'u kadın, 2'si erkekti, yaş ortalamaları 76,4 olarak bulundu. Hastaların17'sinde diafizer femur kırığı, 4'ünde subtrokanterik femur kırığı saptandı. En fazla (%33,3) kullanılan bifosfonatın 70 mg'lık alendronat olduğu saptandı. Ortalama bifosfonat kullanım süresi8,1 yıl idi, ilaca başlanması ve kırık oluşumu arasında geçen süre ortalamasının 7,2 yıl olduğu gözlendi. Kırık oluşumundan önce tüm hastalarda ortalama 8,5 ay süren bir uyluk ağrısının olduğusaptandı. Sonuç: Bifosfonatlar osteoporoz tedavisinde en sık kullanılan ilaçlardandır. Uzun süreli bifosfonat kullanımı olan hastalarda uyluk ağrısının varlığı muhtemel bir atipik kırığın habercisi olabilir

🔖

Cite This Article

ÖZKAN, F. Ü., ÜNAL, Ö. K., KURTULMUŞ, T., TÜRKMEN, İ., SAKA, G., AVCI, C. C., SALAM, N. (2022). UZUN DÖNEM BİFOSFONAT KULLANAN HASTALARDA UYLUK AĞRISI ATİPİK KIRIK HABERCİSİ OLABİLİR. Türk Geriatri Dergisi, Cilt: 18 - Sayı: 1, 87–91. https://ajindex.com/articles/623824

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Varacallo MA, Fox EJ. Osteoporosis and its complications. Med Clin North Am 2014;98(4):817-31. (PMID:24994054). Salari Sharif P, Abdollahi M, Larijani B. Current new and futu- re treatments of osteoporosis. Rheumatol Int 2011;31(3):289- 300. (PMID:20676643). Shane E, Burr D, Ebeling PR et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Mineral Research. J Bone Miner Res 2010;25(11):2267-94. (PMID:20842676). Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyse- al femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 2010;95(12):5258-65. (PMID:20843943). Park-Wyllie LY, Mamdani MM, Juurlink DN et al. Bisphosp- honate use and the risk of subtrochanteric or femoral shaft frac- tures in older women. JAMA 2011;305(8):783-9. (PMID:21343577). Schilcher J, Michaelson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011;364(18):1728-37. (PMID:21542743). Meier RP, Perneger TV, Stern R, Rizzoli R, Peter RE. Increa- sing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 2012;172(12):930-6. (PMID:22732749). Riggs BL, Khosla S, Melton III LJ. Type I/Type II Model for in- volutional osteoporosis. In: Marcus R, Feldman DD, Kelsey J (Eds). Osteoporosis, Academic; San Diego USA 2001, pp 49- 58. Miller RD. Bisphophonates: Pharmacology and use in the tre- atment of osteoporosis; In: Marcus R, Feldman D, Nelson DA, Rosen CJ (Eds). Osteoporosis. 3rd Edition,
  2. Elsevier American Press, San Diego USA 2008, pp 1725-41.
  3. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19(6):733-59. (PMID:18214569). Black DM, Schwartz AV, Ensrud KE et al. Effects of continu- ing or stopping alendronate after 5 years of treatment: the Frac- ture Intervention Trial Long-term Extension (FLEX): a rando- mized trial. JAMA 2006;296(24):2927-38. (PMID:17190893). Levy RN, Capozzi JD, Mont MA. Intertrochanteric hip fractu- res, In:Browner BD, Levine AM, Jupiter JB (Eds). Skeletal Trauma. 3rd edition, Saunders Company, USA 1992, pp 1443- 71. Porrino JA Jr, Kohl CA, Taljanovic M, Rogers. LF. Diagnosis of proximal femoral insufficiency fractures in patients receiving bisphosphonate therapy. AJR Am J Roentgenol 2010;194(4):106